Bioventus Inc. · NASDAQ:BVS
Bioventus — Q1 2021 Earnings Presentation
10 slides from Bioventus's earnings presentation, May 12, 2021
Slide 1: Bioventus: Innovations For Active Healing
@ bioventus Innovations For Active Healing
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this presentation that do not relate to matter
Slide 3: Q1 2021 Results
@bioventus | Q1 2021 Results
Slide 4: CEO Ken Reali commentary on first quarter and Bioness acquisition
“ Bioventus delivered better-than-expected first quarter revenue results, while also completing an important strategic acquisition. Our acquisition of Bioness, a global leader in neuromodulation and advanced rehabilitation medical devices, significantly expands our total addressable market in excess
Slide 5: Revenue Snapshot
Revenue Snapshot Total Q1 2021 Revenue +4.0% y.o.y. Total Q1 2020 Revenue $81.8M $78.6M US Revenue Growth International Revenue Growth +3.6% +8.5% y.o.y. y.o.y.
Slide 6: Revenue Breakdown
Revenue Breakdown Pain Treatments and Joint Bone Graft Substitutes Preservation Revenues + 0.6% y.o.y. Revenues +32.6% y.o.y. Q1 2021: $41.5M Q1 2021: $18.4M Q1 2020: $41.3M Q1 2020: $13.9M Restorative Therapies Revenues –7.0% y.o.y. Q1 2021: $21.8M Q1 2020: $23.5M
Slide 7: Bioventus News
Bioventus News On February 16, 2021, the Company successfully closed its initial public offering (“IPO”). On March 11, 2021, the Company announced that the first patients had been enrolled and dosed in its Phase 1 open-label, dose-escalation study of MOTYS (PTP-001). On March 30, 2021, the Company a
Slide 8: Acquisition - Background
Acquisition - Background Mission Statement: Help improve lives and restore function for those living with neurological deficit and peripheral pain Rehabilitation (85% of revenue) Key Strengths ~$8B+ global TAM ~$6B Post Surgical Pain ~$2B Rehabilitation Alternative to Opioids in pain Major upcoming
Slide 9: Bioventus & Bioness
Bioventus & Bioness Pain Treatments & Joint Restorative Therapies Bone Graft Substitutes Preservation Talisman L360 Products 2021 Revenue ~$200M ~$125M ~$75M ~$400M Rev. (approx.) $2B Global HA $350M Global Bone Healing $2.7B US Orthobiologics TAM $6B Global PNS $1.75B Global Rehabilitation ~$8B ~$2
Slide 10: Bioventus: Innovations For Active Healing
@ bioventus Innovations For Active Healing